[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100446154":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":25,"armGroups":26,"interventions":31,"overallOfficials":21,"centralContacts":37,"locations":43,"responsibleParty":130,"collaborators":21,"id":132,"slug":21,"hasResults":133,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":133,"sex":139,"minAge":140,"maxAge":21,"enrollmentInfo":141,"targetDuration":21,"studyType":144,"phases":21,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":46,"whyStopped":21,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":160},{"fullName":5,"class":6},"Hospices Civils de Lyon","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":21,"otherOutcomes":21},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Liquid biopsy analyses","Extraction of circulating DNA or circulating RNA followed by a tumoral cells extraction.","Day 0",{"measure":14,"description":15,"timeFrame":16},"Standard technics of disease assessment","Genetic and transcriptomic explorations with immunofluorescence technique. Marking with specific markers of the tumor pathology. And enumaration of tumoral cells.","Week 16",{"measure":18,"description":19,"timeFrame":20},"Correlation between outcome 1 and outcome 2","Building a biological collection of blood samples and following, diagnosis and prediction of adult solid cancer.","year 5",null,{"allocation":21,"interventionModel":21,"interventionModelDescription":21,"primaryPurpose":21,"observationalModel":23,"timePerspective":24,"maskingInfo":21},"COHORT","PROSPECTIVE","Adult with solid cancer",[27],{"label":28,"type":21,"description":21,"interventionNames":29},"Adult with solid cancer. No intervention.",[30],"Biological: Blood sampling for biomarker analysis (microRNA, circulating DNA…)",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":21},"BIOLOGICAL","Blood sampling for biomarker analysis (microRNA, circulating DNA…)","From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).",[28],[38],{"name":39,"role":40,"phone":41,"phoneExt":21,"email":42},"Sebastian Couraud, MD, PhD","CONTACT","+33 4 478 864 401","sebastien.couraud@chu-lyon.fr",[44,61,76,86,98,112,121],{"facility":45,"status":46,"city":47,"state":21,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Service de Pneumologie Hôpital Louis Pradel \u002F Groupement Hospitalier Est","RECRUITING","Bron","69500","France","FR",{"type":52,"coordinates":53},"Point",[54,55],4.91303,45.73865,{"lat":55,"lon":54},[58],{"name":59,"role":40,"phone":21,"phoneExt":21,"email":60},"Michaël DURUISSEAUX, Dr","michael.duruisseaux@chu-lyon.fr",{"facility":62,"status":46,"city":63,"state":21,"zip":64,"country":49,"countryCode":50,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Hôpital Edouard Herriot \u002F Groupement Hospitalier Centre","Lyon","69003",{"type":52,"coordinates":66},[67,68],4.84789,45.74906,{"lat":68,"lon":67},[71],{"name":72,"role":40,"phone":73,"phoneExt":74,"email":75},"Mathieu PIOCHE, Pr","04 72 11 01 49","+33","mathieu.pioche@chu-lyon.fr",{"facility":77,"status":46,"city":63,"state":21,"zip":78,"country":49,"countryCode":50,"cosmosGeoPoint":79,"geoPoint":81,"contacts":82},"Service de Pneumologie Hôpital Croix-Rousse \u002F Groupement Hospitalier Nord","69004",{"type":52,"coordinates":80},[67,68],{"lat":68,"lon":67},[83],{"name":84,"role":40,"phone":21,"phoneExt":21,"email":85},"Lize KIAKOUAMA-MALEKA, Dr","lize.kiakouama-maleka@chu-lyon.fr",{"facility":87,"status":46,"city":88,"state":21,"zip":89,"country":49,"countryCode":50,"cosmosGeoPoint":90,"geoPoint":94,"contacts":95},"Service de Pneumologie Aigue Spécialisée et Cancérologie Thoracique Hôpital Lyon-Sud \u002F Groupement Hospitalier Sud","Pierre-Bénite","69310",{"type":52,"coordinates":91},[92,93],4.82424,45.70359,{"lat":93,"lon":92},[96],{"name":97,"role":40,"phone":41,"phoneExt":21,"email":42},"Sebastien COURAUD, MD, PhD",{"facility":99,"status":46,"city":88,"state":21,"zip":100,"country":49,"countryCode":50,"cosmosGeoPoint":101,"geoPoint":103,"contacts":104},"Hôpital Lyon-Sud \u002F Groupement Hospitalier Sud","69495",{"type":52,"coordinates":102},[92,93],{"lat":93,"lon":92},[105,109],{"name":106,"role":40,"phone":107,"phoneExt":74,"email":108},"Olivier GLEHEN, Pr","04 78 86 23 71","olivier.glehen@chu-lyon.fr",{"name":110,"role":40,"phone":107,"phoneExt":74,"email":111},"Vahan KEPENEKIAN, Pr","vahan.kepenekian@chu-lyon.fr",{"facility":113,"status":46,"city":88,"state":21,"zip":100,"country":49,"countryCode":50,"cosmosGeoPoint":114,"geoPoint":116,"contacts":117},"Oncologie médicale Hôpital Lyon-Sud \u002F Groupement Hospitalier Sud",{"type":52,"coordinates":115},[92,93],{"lat":93,"lon":92},[118],{"name":119,"role":40,"phone":21,"phoneExt":21,"email":120},"Gilles FREYER, Pr","gilles.freyer@chu-lyon.fr",{"facility":122,"status":46,"city":88,"state":21,"zip":100,"country":49,"countryCode":50,"cosmosGeoPoint":123,"geoPoint":125,"contacts":126},"Service de dermatologie Hôpital Lyon-Sud \u002F Groupement Hospitalier Sud",{"type":52,"coordinates":124},[92,93],{"lat":93,"lon":92},[127],{"name":128,"role":40,"phone":21,"phoneExt":21,"email":129},"Stéphane DALLE, Pr","stephane.dalle@chu-lyon.fr",{"type":131,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100446154",false,"NCT05089747","CIRculating CANcer MAster-Protocol","MAster Protocol Studying the Impact of Blood Biopsy on Screening, Diagnosis, Diagnostic and Follow-up of Solid Cancer in Adult","CIRCAN MAP","Inclusion Criteria:\n\n* Adult (\\>18y)\n* Owing a social security insurance\n* Any solid cancer diagnosed by histopathology or cytology\n* Patient with blood sampling required as per standard of care\n* Informed consent signed\n\nExclusion Criteria:\n\n* Refusal to participate\n* No blood sampling required as per standard of care\n* Hemoglobin \\\u003C 7g\u002Fdl (\\\u003C 9g\u002Fdl if respiratory or cardiovascular disease history)\n* Heterologous blood transfusion in the last 48 hours\n* Weight under 20 kg","ALL","18 Years",{"count":142,"type":143},6000,"ESTIMATED","OBSERVATIONAL","This exploratory study will focus on the development of the analyses of blood biomarkers to better understand the circulating biomarkers associated with cancer diagnosis, treatment efficacy and progressive disease",[147],"Adult With Solid Cancer",[149,150],"liquid biopsy","solid cancer","2026-06-08",{"date":153,"type":154},"2026-06-10","ACTUAL",{"date":156,"type":154},"2022-12-05",{"date":158,"type":143},"2047-12-01",{"name":5,"class":6},7]